Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Roche's Trontinemab?
Trontinemab is a fusion protein commercialized by Roche, with a leading Phase II program in Alzheimer's Disease. According to Globaldata,...